Cerebrolysin enhances the expression of the synaptogenic protein LRRTM4 in the hippocampus and improves learning and memory in senescent rats.

Flores-Páez LA, Pacheco-Rosado J, Alva-Sánchez C, Zamudio SR

Behavioural pharmacology1 Aug 2020Cited by 10 (Europe PMC)

PMID31850962DOI10.1097/fbp.0000000000000530PepBankPUB-31850962

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In aging rats, Cerebrolysin attenuated impaired acoustic startle habituation compared with vehicle.
In plain wordsIn aging rats, Cerebrolysin reduced impaired habituation to acoustic startle compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseAcoustic startle habituation
Study
ratsn: not reported in source
15-month-old Wistar rats
Comparator
Age-matched vehicle-treated rats
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
1076 mg/kg · intraperitoneal · 4 weeksAs given in this study (rats).
Source sentences
Summary
These impairments were attenuated by the subchronic cerebrolysin treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
The 15-month-old vehicle-treated rats showed impairments in the habituation of the acoustic startle response and in learning and memory when compared to 3-month-old rats.
Summary · context
The aim of this study was to evaluate the effect of the cerebrolysin treatment on the learning and memory abilities, sensorimotor functions, and the leucine-rich repeat transmembrane 4 protein expression in the brain of 15-month-old rats.
Summary · context
Cerebrolysin (1076 mg/kg) or vehicle was administered to Wistar rats intraperitoneally for 4 weeks.
Report a problemFND-3185096201
02AnimalAnimal study (in vivo)Efficacy outcome
In aging rats, Cerebrolysin attenuated learning impairment compared with vehicle.
In plain wordsIn aging rats, Cerebrolysin reduced learning impairment compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseLearning
Study
ratsn: not reported in source
15-month-old Wistar rats
Comparator
Age-matched vehicle-treated rats
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
1076 mg/kg · intraperitoneal · 4 weeksAs given in this study (rats).
Source sentences
Summary
These impairments were attenuated by the subchronic cerebrolysin treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
The 15-month-old vehicle-treated rats showed impairments in the habituation of the acoustic startle response and in learning and memory when compared to 3-month-old rats.
Summary · context
The aim of this study was to evaluate the effect of the cerebrolysin treatment on the learning and memory abilities, sensorimotor functions, and the leucine-rich repeat transmembrane 4 protein expression in the brain of 15-month-old rats.
Summary · context
Cerebrolysin (1076 mg/kg) or vehicle was administered to Wistar rats intraperitoneally for 4 weeks.
Report a problemFND-3185096202
03AnimalAnimal study (in vivo)Efficacy outcome
In aging rats, Cerebrolysin attenuated memory impairment compared with vehicle.
In plain wordsIn aging rats, Cerebrolysin reduced memory impairment compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseMemory
Study
ratsn: not reported in source
15-month-old Wistar rats
Comparator
Age-matched vehicle-treated rats
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
1076 mg/kg · intraperitoneal · 4 weeksAs given in this study (rats).
Source sentences
Summary
These impairments were attenuated by the subchronic cerebrolysin treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
The 15-month-old vehicle-treated rats showed impairments in the habituation of the acoustic startle response and in learning and memory when compared to 3-month-old rats.
Summary · context
The aim of this study was to evaluate the effect of the cerebrolysin treatment on the learning and memory abilities, sensorimotor functions, and the leucine-rich repeat transmembrane 4 protein expression in the brain of 15-month-old rats.
Summary · context
Cerebrolysin (1076 mg/kg) or vehicle was administered to Wistar rats intraperitoneally for 4 weeks.
Report a problemFND-3185096203
04AnimalAnimal study (in vivo)Mechanism
In aging rats, Cerebrolysin attenuated the decline in hippocampal LRRTM4 expression compared with vehicle.
In plain wordsIn aging rats, Cerebrolysin reduced the decline in hippocampal LRRTM4 protein compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseHippocampal LRRTM4 expression
Study
ratsn: not reported in source
15-month-old Wistar rats
Comparator
Age-matched vehicle-treated rats
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1076 mg/kg · intraperitoneal · 4 weeksAs given in this study (rats).
Source sentences
Summary
The leucine-rich repeat transmembrane 4 protein expression was lower in the old vehicle-treated rats than in the young rats; the cerebrolysin treatment attenuated that decrease in the old rats.
3 context sentences(design, population, supporting numbers)
Summary · context
Finally, the leucine-rich repeat transmembrane 4 expression was measured in the brainstem, striatum, and hippocampus using a Western-blot assay.
Summary · context
The aim of this study was to evaluate the effect of the cerebrolysin treatment on the learning and memory abilities, sensorimotor functions, and the leucine-rich repeat transmembrane 4 protein expression in the brain of 15-month-old rats.
Summary · context
Cerebrolysin (1076 mg/kg) or vehicle was administered to Wistar rats intraperitoneally for 4 weeks.
Report a problemFND-3185096204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.